Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Economic information and modeling report

Modeling overview

36 evidence topics · 26 sources

Summary: scope of the economic evidence

Envudeucitinib is an investigational drug. No cost-effectiveness, cost per responder, or budget impact analysis that includes envudeucitinib was found, and the report records no price for it. The evidence under this heading covers comparator prices from state, federal, and manufacturer sources; the 2016 and 2018 ICER assessments of targeted immunomodulators for plaque psoriasis; published cost-effectiveness, cost per responder, and budget impact analyses of comparators; and market statements by Alumis.

Summary: comparator prices by source

Prices are given as each source lists them, in U.S. dollars.

  • Texas DSHS 2026 annual WAC report: Sotyktu 7135.55; TREMFYA 14566.44; TALTZ 7624.59; BIMZELX 160MG/ML auto-injector pen 8350.73; STELARA 29151.48 and 29151.46 (two NDCs); Otulfi 45 MG/0.5ML 1809.79; SELARSDI 45MG/0.5ML 2088.21; HUMIRA PEN 6922.62.
  • California HCAI WAC increase file, January to October 2026: Otezla 30mg 60 pack and Otezla 75 mg extended-release 30 pack 5589.89 each (effective 01/07/2026); SKYRIZI PEN 150 mg 23838.42 (01/02/2026); COSENTYX 150 mg pen 8165.42 and 300 mg pen 8492.03 (01/07/2026); Enbrel Sureclick 50mg 4 pack 8565.48 (01/07/2026); SILIQ 210mg box of 2 syringes 6928.92 (05/11/2026); Cimzia 2 x 200 mg kit 6299.40 (01/01/2026).
  • California HCAI new prescription drugs file: ICOTYDE 200mg tablet, package size 30, WAC at introduction 8285.0000 on 2026-03-18, with an estimated patient count of 8000000 in the filing.
  • Department of Veterans Affairs Federal Supply Schedule, from 01/01/2026 unless noted: SOTYKTU 6MG TAB (30) FSS 6088.27 and Big Four 4815.81; OTEZLA 30MG TAB (60) 3495.82; OTEZLA XR 75MG TAB (30) 4775.29 from 01/29/2026; TREMFYA 100MG/ML 13931.32; SKYRIZI 150MG/ML 15522.22; STELARA 45MG/0.5ML 13980.15; ILUMYA 100MG/ML 11842.56; COSENTYX PEN (2 PENS) 6835.37; ENBREL 50MG/ML SURECLICK (4) 6933.40; HUMIRA 40MG/0.4ML (2) 5879.01.
  • CMS Medicare Part B payment limits effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data, per 1 mg: tildrakizumab 120.965, guselkumab 66.998, risankizumab 14.011, intravenous secukinumab 18.131, intravenous ustekinumab 10.249, and certolizumab pegol 3.140; infliximab 29.856 per 10 mg.
  • Medicare negotiation: the negotiated price for Otezla and Otezla XR (Amgen Inc.) is $1,650 for a 30-day supply in CY 2027, a 65% discount from the CY 2024 list price of $4,722; 31,000 Medicare Part D enrollees used the drug in CY 2024, with $1,045,443,000 in total Part D gross covered prescription drug costs. Cosentyx and Cimzia were selected for the third cycle of negotiation, with any negotiated prices effective beginning in 2028.
  • Bristol Myers Squibb offers Sotyktu to eligible cash-pay U.S. patients through BMS Patient Connect, beginning January 2026, at more than 80% less than the current list price.

Summary: ICER assessments of targeted immunomodulators

  • 2016 report: cost per QALY versus non-targeted therapy was $89,610 for apremilast, $89,843 for secukinumab, $92,715 for infliximab, $94,030 for brodalumab, $100,389 for ixekizumab, $108,040 for adalimumab, $117,769 for etanercept, and $129,904 for ustekinumab; results for brodalumab were tentative because pricing was not available. Using WAC prices, the ratios ranged from $140,000 to $187,000 per QALY gained. All drugs except adalimumab, apremilast, and infliximab required discounts from WAC to fall within the threshold range of $100,000 to $150,000/QALY. The candidate population, adults with moderate-to-severe plaque psoriasis taking a biologic agent for the first time, was approximately 36,750 incident cases per year; against a threshold of $904 million per year for 2015-16, the potential budgetary impact averaged approximately $239.8 million per year for brodalumab and approximately $266 million per year for ixekizumab.
  • 2018 report: net prices for all drugs except infliximab were derived from SSR Health, LLC. The cost-effectiveness table gives cost per QALY versus non-targeted treatment from $131,000 for brodalumab to $188,000 for certolizumab pegol, with $135,000 for apremilast; the text gives the base-case range as $133-$188K/QALY and states that including productivity offsets lowered the ratios to $109-166K/QALY. At a $50K/QALY threshold no targeted drugs offered good value, and at a $100,000 per QALY threshold, initiation with brodalumab or infliximab each had a 10% probability of being optimal value. Annual discounts required to reach $100,000 per QALY ranged from 38% to 71%, and to reach $150,000 per QALY from 8% to 44%; for apremilast, the annual WAC was $40,000, the estimated net price $31,000, and the price to achieve $100,000 per QALY $17,500. The report states that IL-17 drug prices had increased since the 2016 report.
  • 2018 budget impact: 29,342 incident cases of moderate-severe plaque psoriasis per year (approximately 146,710 over five years); at all prices except the price to reach $50,000 per QALY, the annual potential budgetary impact exceeded the threshold of $915 million, with an additional per-patient cost of approximately $58,900 at WAC and approximately $37,200 with the assumed discount.

Summary: cost-effectiveness and cost per responder analyses of comparators

  • Hendrix et al.: in a 10-year Markov model with WAC discounted by a class-specific rebate percentage off 2016 costs, costs of care without targeted treatment totaled $66,451 and costs of targeted treatment ranged from $137,080 (apremilast) to $255,422 (ustekinumab); infliximab and apremilast were likely to be the most cost-effective initial treatments at thresholds around $100,000 per QALY, and IL-17 drugs at thresholds approaching $150,000 per QALY.
  • Jia et al.: over 10 years, the incremental cost per QALY gained was lowest for brodalumab, infliximab, apremilast, and tildrakizumab.
  • Kong and Buzney: mean annual total costs were $84,034 for biologics, $14,760 for office phototherapy, and $6222 for home phototherapy, with mean QALY gains of 0.24 for biologics, 0.18 for phototherapy, and 0.23 for step therapy.
  • Egilman et al.: U.S. net prices of 13 biologic therapies ranged from $1664 to $79,277 per year, with a median net annual treatment cost of $34,965; U.S. prices would need a median reduction of 71% to align with efficiency frontier estimates.
  • Park et al.: the cost per response of deucravacitinib versus apremilast was lower at 16 weeks (difference -$3796) and 24 weeks (difference -$12,784), and at 52 weeks the cost per cumulative benefit was lower for patients who initiated deucravacitinib.
  • Wu et al. (cost per month with a PASI 75 response): the incremental cost per extra month with a PASI 75 response ranged from $3,685 for brodalumab to $13,476 for certolizumab pegol, with $4,770 for apremilast. Wu et al. (annual cost per response): the annual cost per PASI 75 was $48,782 for brodalumab and $87,243 for ustekinumab.
  • Teeple and Muser and Teeple and Fitzgerald: the cost per PASI 90 response was $113,861 for guselkumab against $151,226 for adalimumab in the induction year, and $89,960 for guselkumab against $110,977 for secukinumab at 48 weeks.
  • Blauvelt et al.: over 16 weeks, guselkumab had the lowest cost per cumulative benefit for PASI 90 ($99,742) and ixekizumab for PASI 100 ($230,884).
  • McCoy et al.: NB-UVB had an adjusted monthly cost of $1714.00 per PASI 75, and infliximab, the least expensive biologic, $2076.00 to $2502.00.

Summary: published budget impact analyses of comparators

  • Carrico et al.: a health plan of 1,000,000 members, with psoriasis prevalence of 3.2%, 90.0% with plaque psoriasis, 18.2% with moderate-to-severe disease, 20.0% treated with a biologic or apremilast, and 35.6% new users, had an estimated 1048 patients receiving biologics or apremilast. Adding tildrakizumab reduced total annual health plan cost by $5585 in year 1 and $342,563 in year 5, a cumulative $964,763 over 5 years, with per member per month reductions of $0.03 or less. Acquisition costs were based on WACs from May 2019.
  • Feldman et al.: in a hypothetical commercial health plan of two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for brodalumab; the total annual pharmacy budget for biologics without brodalumab was $414,362,647, and brodalumab use of 3%, 8%, 16%, and 30% reduced it by $3,698,129, $9,861,677, $19,723,355, and $36,981,290.

Summary: market statements by Alumis

In its corporate presentation, Alumis describes psoriasis as a “Large marketplace with modest treatment penetration”, states that historical market share trends show a multi-winner market and that the uptake of Icotyde is largely additive, and reports that 84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies. In its annual report, Alumis states that the precise incidence and prevalence for the conditions it aims to address are unknown, that its estimates derive from sources including sales of competitors and market research and may prove to be incorrect, and that pricing of competitive products may limit the amount it will be able to charge for its product candidates, if approved.

Wholesale acquisition cost of deucravacitinib in the Texas 2026 annual report

Wholesale acquisition costs of injectable biologics and ustekinumab biosimilars in the Texas 2026 annual report

Federal Supply Schedule and Big Four prices for oral and injectable comparators

ProductTrade namePackage descriptionPrice typePricePrice start datePrice stop date
Deucravacitinib 6 mg“SOTYKTU 6MG TAB”“30”FSS“6088.27”“01/01/2026”“04/30/2029”
Deucravacitinib 6 mg“SOTYKTU 6MG TAB”“30”Big Four“4815.81”“01/01/2026”“04/30/2029”
Apremilast 30 mg“OTEZLA 30MG TAB”“60”FSS and Big Four“3495.82”“01/01/2026”“07/31/2026”
Apremilast 75 mg extended release“OTEZLA XR 75MG TAB”“30”FSS“4775.29”“01/29/2026”“07/31/2026”
Guselkumab 100 mg“TREMFYA 100MG/ML INJ”“1ML”FSS“13931.32”“01/01/2026”“08/31/2029”
Risankizumab 150 mg“SKYRIZI 150MG/ML INJ,SYRINGE,KIT”“1ML”FSS“15522.22”“01/01/2026”“07/31/2030”
Ustekinumab 45 mg“STELARA 45MG/0.5ML PFS (ULTRA-SAFE)”“1X45MG/0.5ML”FSS“13980.15”“01/01/2026”“08/31/2029”
Tildrakizumab 100 mg“ILUMYA 100MG/ML INJ,SYRINGE,1ML”“1ML”FSS“11842.56”“01/01/2026”“07/14/2026”
Secukinumab 150 mg“COSENTYX PEN (2 PENS)”“2X1ML”FSS“6835.37”“01/01/2026”“08/31/2026”
Etanercept 50 mg“ENBREL 50MG/ML SURECLICK AUTOINJECTOR”“4”FSS“6933.40”“01/01/2026”“07/31/2026”
Adalimumab 40 mg“HUMIRA 40MG/0.4ML INJ,SYRINGE,PEN”“2”FSS“5879.01”“01/01/2026”“07/31/2030”

Medicare negotiated price for apremilast effective January 2027

FieldQuoted value
Drug name“Otezla; Otezla XR”
Participating drug company“Amgen Inc.”
Agreed to negotiated price for 30-day supply for CY 2027“$1,650”
List price for 30-day supply, CY 2024“$4,722”
Discount of negotiated price from 2024 list price“65%”
Total Part D gross covered prescription drug costs, CY 2024“$1,045,443,000”
Number of Medicare Part D enrollees who used the drug, CY 2024“31,000”

Drug cost inputs and estimated net prices in the 2018 ICER assessment

Costs, QALYs, and cost per QALY of first-line targeted therapies in the 2018 ICER assessment

First-line treatmentTotal costTotal QALYsCost per QALY versus non-targeted treatmentCost per month in PASI 75 or better
Non-targeted treatment“$67,800”“5.70”Not applicableNot applicable
Adalimumab“$308,000”“7.17”“$164,000”“$3,200”
Apremilast“$215,000”“6.79”“$135,000”“$2,800”
Brodalumab“$289,000”“7.39”“$131,000”“$2,600”
Certolizumab pegol“$341,000”“7.16”“$188,000”“$3,700”
Etanercept“$272,000”“6.88”“$175,000”“$3,500”
Guselkumab“$342,000”“7.40”“$161,000”“$3,200”
Infliximab“$238,000”“6.98”“$134,000”“$2,700”
Ixekizumab“$311,000”“7.42”“$142,000”“$2,800”
Secukinumab“$305,000”“7.34”“$145,000”“$2,900”
Ustekinumab“$315,000”“7.17”“$169,000”“$3,300”

“In the base-case, ixekizumab has an ICER of $142,000 per QALY compared to non-targeted, and an ICER of $72,000 per QALY compared to etanercept.” (opens the source at this quote in a new tab)

“These results indicate that at a $50K/QALY threshold, no targeted drugs offer good value; at a $100K/QALY threshold, initiation with brodalumab or infliximab each have a 10% probability of being optimal value, and probabilities for the other targeted agents are all near zero; and at a $150K/QALY threshold there is more separation, as initiation with brodalumab or infliximab is most likely to be cost effective, while the other IL-17s and guselkumab have somewhat lower probabilities of being most cost effective.” (opens the source at this quote in a new tab)

“Including productivity offsets led to 10-13% decreases in total costs, and ICER’s compared to non-targeted that were notably lower than in the base case (i.e., $109-166K/QALY rather than $133-$188K/QALY).” (opens the source at this quote in a new tab)

“Our analysis indicates first-line treatment with infliximab or the IL-17 drugs is cost effective at higher willingness to pay thresholds, and infliximab and brodalumab are most likely to be cost effective.” (opens the source at this quote in a new tab)

“Guselkumab may be cost effective depending on drug discounts, and apremilast, while the least effective drug, may be cost effective at moderate willingness to pay thresholds.” (opens the source at this quote in a new tab)

“Among the IL-17’s, initiation with brodalumab appears to be the most cost-effective strategy due to drug pricing.” (opens the source at this quote in a new tab)

“Of note, the IL-17 drug prices have increased, leading to less favorable value than in our 2016 report.” (opens the source at this quote in a new tab)

Value-based price benchmarks in the 2018 ICER assessment

DrugAnnual WACAnnual estimated net priceAnnual price to achieve $100,000 per QALYAnnual price to achieve $150,000 per QALYDiscount from WAC required to reach threshold prices
Adalimumab“$63,600”“$43,700”“$25,700”“$39,800”“37% to 60%”
Apremilast“$40,000”“$31,000”“$17,500”“$36,600”“8% to 56%”
Brodalumab“$45,700”“$36,500”“$28,200”“$41,500”“9% to 38%”
Certolizumab pegol“$79,100”“$50,600”“$25,500”“$39,700”“43% to 63%”
Etanercept“$63,600”“$43,700”“$18,500”“$35,400”“44% to 71%”
Guselkumab“$66,300”“$44,400”“$28,400”“$41,500”“37% to 57%”
Infliximab“$38,100”“$29,700”“$18,800”“$35,000”“8% to 51%”
Ixekizumab“$67,300”“$37,700”“$27,100”“$39,700”“41% to 60%”
Secukinumab“$61,500”“$38,200”“$25,500”“$39,400”“36% to 59%”
Ustekinumab“$58,200”“$42,600”“$25,200”“$37,800”“35% to 57%”
RisankizumabNot availableNot available“$27,300”“$39,800”Not available
TildrakizumabNot availableNot available“$23,000”“$36,800”Not available

Eligible population and potential budget impact in the 2018 ICER assessment

“The potential budget impact analysis included the entire candidate population for treatment, which included adults with moderate to severe plaque psoriasis who are taking a biologic agent for psoriasis for the first time.” (opens the source at this quote in a new tab)

“Psoriasis incidence in the United States has been estimated at 78.9 cases per 100,000 persons.” (opens the source at this quote in a new tab)

“Applying these proportions to the projected 2018-2022 U.S. adult population results in an average estimate of 29,342 incident cases of moderate-severe plaque psoriasis in the US per year, or approximately 146,710 incident cases over five years, assuming equal incidence rates for each of” (opens the source at this quote in a new tab)

“the five years in our analysis.” (opens the source at this quote in a new tab)

“For 2017-18, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately $915 million per year for new drugs.” (opens the source at this quote in a new tab)

“At all prices except the price to reach the $50,000 per QALY threshold, the annual potential budgetary impact for the entire eligible population exceeded the ICER annual budget impact threshold of $915 million.” (opens the source at this quote in a new tab)

“The average potential budgetary impact when using the WAC was an additional per-patient cost of approximately $58,900 and approximately $37,200 using the assumed discount from WAC.” (opens the source at this quote in a new tab)

Base-case costs, QALYs, and cost per QALY in the 2016 ICER assessment

Value-based price benchmarks per unit in the 2016 ICER assessment

Ten-year cost-effectiveness of eight targeted therapies in a U.S. Markov model

TreatmentCost, $QALYsICER, $/QALYICER versus etanercept, $/QALY
No treatment“66,451”View highlighted excerpt for this quote“5.531”View highlighted excerpt for this quoteNot applicableNot applicable
Apremilast“137,080”View highlighted excerpt for this quote“6.403”View highlighted excerpt for this quote“81,033 (vs. no treatment)”View highlighted excerpt for this quoteNot applicable
Etanercept“181,387”View highlighted excerpt for this quote“6.505”View highlighted excerpt for this quote“433,248 (vs. apremilast)”View highlighted excerpt for this quoteNot applicable
Adalimumab“194,180”View highlighted excerpt for this quote“6.681”View highlighted excerpt for this quote“72,703 (vs. etanercept)”View highlighted excerpt for this quote“72,703”View highlighted excerpt for this quote
Infliximab“176,695”View highlighted excerpt for this quote“6.804”View highlighted excerpt for this quote“Dominant”View highlighted excerpt for this quote“Dominant”View highlighted excerpt for this quote
Ustekinumab“255,422”View highlighted excerpt for this quote“6.959”View highlighted excerpt for this quote“Dominated”View highlighted excerpt for this quote“162,923”View highlighted excerpt for this quote
Secukinumab“208,727”View highlighted excerpt for this quote“7.045”View highlighted excerpt for this quote“132,913 (vs. infliximab)”View highlighted excerpt for this quote“50,661”View highlighted excerpt for this quote
Brodalumab“236,690”View highlighted excerpt for this quote“7.173”View highlighted excerpt for this quote“217,589 (vs. secukinumab)”View highlighted excerpt for this quote“82,766”View highlighted excerpt for this quote
Ixekizumab“243,938”View highlighted excerpt for this quote“7.208”View highlighted excerpt for this quote“208,872 (vs. brodalumab)”View highlighted excerpt for this quote“88,991”View highlighted excerpt for this quote

Cost-effectiveness of tildrakizumab and other first-line targeted therapies over 10 years

U.S. net prices of psoriasis biologics and price reductions under an efficiency frontier

Budget impact of adding tildrakizumab to a U.S. health plan of 1 million members

Population characteristicBase case
Number of members in health plan“1,000,000”View highlighted excerpt for this quote
Prevalence of psoriasis“3.2%”View highlighted excerpt for this quote
Proportion with plaque psoriasis“90.0%”View highlighted excerpt for this quote
Proportion with moderate-to-severe psoriasis“18.2%”View highlighted excerpt for this quote
Proportion treated with a biologic or apremilast“20.0%”View highlighted excerpt for this quote
New biologic or apremilast treatment users (require induction dosing)“35.6%”View highlighted excerpt for this quote

Economic analyses that include envudeucitinib

No evidence found.